Cavanaugh Sarah reported CLDX

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001709113-26-000002

Machine-readable

Structured copy

Timestamps

Event (reported)

Jun 25, 2026

Published

Jun 29, 2026

Ingested by INSIDER

Nov 5, 03:50 UTC

Last re-read

Nov 5, 03:50 UTC

Extracted facts

Filer

Cavanaugh Sarah

Role

SVP OF CORP AFFAIRS & ADMIN.

Transaction

Grant or awardAs filed: “A”

Asset

Celldex Therapeutics, Inc. — Incentive Stock Option (right to buy)

Ticker

CLDX

Shares

95.0K

Price per share

$0

Execution date (reported)

Jun 25, 2026

Owned after transaction

95.0K shares

Days from execution to publication

4

What this establishes

Cavanaugh Sarah filed this Form 4 reporting a grant or award of CLDX on Jun 25, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

SVP OF CORP AFFAIRS & ADMIN.

Cavanaugh Sarahcik:0001709113

Issuer

Celldex Therapeutics, Inc.cik:0000744218

Revision history · 0

No field has changed since this record was first ingested.